Sólja Remisdóttir Remisdóttir Veyhe

Ms. Sólja Remisdóttir Remisdóttir Veyhe


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in BioTechniques
Verified
Journal Article
Open access
OCOriane Cédile
Oriane Cédile
SVSólja Remisdóttir Remisdóttir Veyhe
Sólja Remisdóttir Remisdóttir Veyhe
MHMarcus Høy Hansen
Marcus Høy Hansen
KTKjell Titlestad
Kjell Titlestad
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
Method summary Concentrations of circulating DNA in blood plasma were compared using NanoDrop, Qubit, quantitative PCR and Bioanalyzer, and DNA integrity was evaluated with the Bioanalyzer accordin...

Verified
Journal Article
Open access
PDF file
SVSólja Remisdóttir Remisdóttir Veyhe
Sólja Remisdóttir Remisdóttir Veyhe
OCOriane Cédile
Oriane Cédile
SDSara Kamuk Dahlmann
Sara Kamuk Dahlmann
JKJakub Krejcik
Jakub Krejcik
NANiels Abildgaard
Niels Abildgaard
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells due to constitutive B-cell receptor (BCR) signaling, leading to apoptosis resistance and increased proliferation. This study evaluates the effects of the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib on the molecular composition, clonality, and kinetics of B cells during treatment in CLL patients. Employing a multi-omics approach of up to 3.2 years of follow-up, we analyzed data from 24 CLL patients, specifically focusing on nine patients treated with ibrutinib monotherapy. In this study, clonal stability was observed within the ibrutinib-treated group following an effective initial clinical response, where clonotype frequencies of residual CLL cells remained high and stable, ranging from 74.9% at 1.5 years to 87.7% at approximately 3 years. In contrast, patients treated with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax exhibited substantial reductions in clonal frequencies, approaching molecular eradication. Deep whole-exome sequencing revealed minimal genomic progression in the ibrutinib group, maintaining somatic drivers and variant allele frequencies (VAF) above 0.2 throughout treatment. At the single-cell level, the NF-κB pathway inhibition and apoptotic signals were detected or even augmented during treatment in ibrutinib-treated patients. These findings may corroborate the role of ibrutinib in stabilizing the genomic landscape of CLL cells, preventing significant genomic evolution despite maintaining a high clonal burden within the residual B-cell compartment.

8 September 2025 in European Journal of Haematology
Verified
Journal Article
Open access
MHMarcus Høy Hansen
Marcus Høy Hansen
RGRona Gulmir
Rona Gulmir
OCOriane Cédile
Oriane Cédile
SDSara Kamuk Dahlmann
Sara Kamuk Dahlmann
SVSólja Remisdóttir Remisdóttir Veyhe
Sólja Remisdóttir Remisdóttir Veyhe
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
Background: Clonotyping of immunoglobulin heavy chain (IGH) gene rearrangements is critical for diagnosis, prognostication, and measurable residual disease monitoring in chronic lymphocytic leukemia (CLL). Although short‐read next‐generation sequencing (NGS) platforms, such as Illumina MiSeq, are widely used, they face challenges in spanning full VDJ rearrangements. Long‐read sequencing via Oxford Nanopore Technologies (ONT) offers a potential alternative using the compact and cost‐effective flow cells. Methods: We evaluated IGH clonotyping in samples from 13 CLL patients using ONT MinION with Flongle flow cells and super‐accuracy GPU‐based base calling (Dorado), comparing results to MiSeq‐based LymphoTrack assays. Amplicons were generated using the IGH FR1 assay and analyzed using Smith‐Waterman alignment and IgBlast tools. Results: All major and minor clonotypes identified by MiSeq were matched with 100% sequence identity using Nanopore sequencing. Clonal burden estimates were strongly correlated (Pearson ρ = 0.87, p < 10 −4 ), although with considerable variability. Somatic hypermutation status was reliably assessed with super‐accuracy base calling (Q30: 76%). Fast or CPU‐only base calling was insufficient for accurate mutation analysis. Conclusion: Nanopore sequencing enables accurate and rapid IGH clonotyping in CLL, offering comparable performance to MiSeq with lower cost and laboratory footprint. This supports its potential utility in routine and decentralized hematopathology workflows.

23 February 2025 in European Journal of Haematology
Verified
Journal Article
Open access
SVSólja Remisdóttir Remisdóttir Veyhe
Sólja Remisdóttir Remisdóttir Veyhe
MHMarcus Høy Hansen
Marcus Høy Hansen
OCOriane Cédile
Oriane Cédile
MMMichael Boe Møller
Michael Boe Møller
MNMie Kiszka Nielsen
Mie Kiszka Nielsen
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
Patients with chronic lymphocytic leukemia (CLL) undergoing ibrutinib treatment often experience incomplete response, yet the molecular level underlying clonal inertia remains to be explored. We investigated the molecular and clinical dynamics of CLL during 16 months of ibrutinib monotherapy by analyzing blood samples from two patients who continued having CLL cells in the peripheral blood during treatment. At diagnosis, the clonal burden within the B cell compartment was found to be 55% (pt1) and 86% (pt2) for the dominant clones. At 16 months following treatment these clones still constituted 66% and 89%, respectively. Utilizing multi‐omic methodologies at the DNA and RNA levels, including single‐cell transcriptomics, we aimed to establish a comprehensive framework for multi‐omics analysis for longitudinal ibrutinib response evaluation. The presented study revealed genomically stable disease during ibrutinib treatment, but with intensified expression of genes involved in pathways related to apoptosis, cellular stress response, and canonical NF‐κB signaling from diagnosis to 16 months of treatment.